Revenue
0 USD
2022 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
PARDES BIOSCIENCES, INC.
EDGAR16 filing records in this dataset, filed from 2021-01-26 to 2023-08-04. Reported financial figures are available; chart coverage varies by period.
Latest fiscal year
Operating cash flow
-72 million USD
2022 · USD
Exact inputs and evidence
- Operating Cash Flow: -71976000 USD Source
- Cash and cash equivalents
- 100 million USD Source
Exact value
100266000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 60.4 million shares Source
Exact value
60396888 shares
Reported share-count change
4.17% · 2.42 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-76.1 million USD
2022-07-01 – 2023-06-30
Exact inputs and evidence
Operating cash flow
-78.7 million USD
2022-07-01 – 2023-06-30
Exact inputs and evidence
- Operating cash flow: -59226000 USD · 2022-01-01 – 2022-09-30 Source
- Operating cash flow: -39682000 USD · 2022-01-01 – 2022-06-30 Source
- Operating cash flow: -71976000 USD · 2022-01-01 – 2022-12-31 Source
- Operating cash flow: -59226000 USD · 2022-01-01 – 2022-09-30 Source
- Operating cash flow: -26533000 USD · 2023-01-01 – 2023-03-31 Source
- Operating cash flow: -46444000 USD · 2023-01-01 – 2023-06-30 Source
- Operating cash flow: -26533000 USD · 2023-01-01 – 2023-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2023-08-04.
Financial data available through: 2022-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2022-12-31
- Operating income: 1 of 11 periods available· newest 2021-12-31
- Net income: 2 of 11 periods available· newest 2022-12-31
- Operating cash flow: 2 of 11 periods available· newest 2022-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 2 of 11 periods available· newest 2022-12-31
- Total liabilities: 2 of 11 periods available· newest 2022-12-31
- Current assets: 2 of 11 periods available· newest 2022-12-31
- Current liabilities: 2 of 11 periods available· newest 2022-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2022-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2022-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
USD 0Prior period
USD 0
–
Current period
USD 0
–
Exact inputs and evidence
0 − 0 = 0 USD
0 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source0 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 58.12 millionPrior period
−USD 38.52 million
–
Current period
−USD 96.63 million
–
Exact inputs and evidence
-96634000 − -38518000 = -58116000 USD
-38518000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source-96634000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 35.06 millionPrior period
−USD 36.92 million
–
Current period
−USD 71.98 million
–
Exact inputs and evidence
-71976000 − -36918000 = -35058000 USD
-36918000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source-71976000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2022 2022-01-01 – 2022-12-31
- Revenue USD 0
- Operating costs Derived Unavailable An input is unavailable.
- Operating income Unavailable An input is unavailable.
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income −USD 96.63 million
Cash
- Operating cash flow −USD 71.98 million
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2021 Not shown: operating income or net income is not reported.
- 2022 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | 0 | -38488000 Derived | 38488000 | 77006000 Derived | -38518000 | Unavailable | Source
|
| 2022 2022-01-01 – 2022-12-31 | 0 | Unavailable | Unavailable | Unavailable | -96634000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 0 2022
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2021 | Revenue | 0 |
|
| 2022 | Revenue | 0 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Year over year | No prior comparable period |
|
| 2022 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Operating margin | Not reported |
|
| 2022-12-31 | Operating margin | Not reported |
|
| 2021 | Net margin | Not reported |
|
| 2022 | Net margin | Not reported |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -72M 2022
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2021 | Operating cash flow | -36918000 |
|
| 2022 | Operating cash flow | -71976000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
10.2% 2022
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Liabilities / assets | 3.3% |
|
| 2022 | Liabilities / assets | 10.2% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
9.81× 2022
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Current assets / current liabilities | 30.7× |
|
| 2022 | Current assets / current liabilities | 9.81× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | −USD 38.52 million Exact valueExact value: -38518000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 36.92 million Exact valueExact value: -36918000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 96.63 million Exact valueExact value: -96634000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 71.98 million Exact valueExact value: -71976000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
16 filings · 564 latest values · 564 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001822711, 1822711, FSII, PRDS, edgar:1822711
Also known as FS DEVELOPMENT CORP. II, FS Development Corp. II, PARDES BIOSCIENCES, INC.